ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses. Patients with extensive-stage small cell lung ...

Wearable activity monitors could be useful in assessing the health of cancer patients and making predictions about mortality and adverse events, according to a study published last week in Nature's ...

Performance status is prognostic in oncology and palliative care settings. Traditionally clinician rated, it is often inconsistently collected, recorded, and measured, thereby limiting its utility.

ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...

Performance status (PS) is assessed during cancer treatment to determine clinical trial eligibility, appropriateness for treatment, and need for supportive care. There is rising interest for patients ...

The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

Accurately diagnosing and staging patients with upper tract urothelial carcinoma (UTUC) has proven challenging for clinicians. Experts at Memorial Sloan Kettering recently applied genomic sequencing ...

Please provide your email address to receive an email when new articles are posted on . Patient-reported physical function predicts which patients gain greatest survival benefit from daratumumab.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...